Gastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks Clinical Trial
Background: Gastric cancer (GC) is major global health concern and the second leading cause
of cancer deaths worldwide. Amplification of Her2/neu gene and/or overexpression of the
Her2/neu protein have been observed in GC. Trastuzumab (Herceptin™) is an anti-Her2/neu
antibody, which has been successfully applied in GC. However, the intratumoral heterogeneity
of Her2/neu overexpression and amplification in GC should be noticed. The investigators
investigated the significance of evaluating Her2/neu expression in different paraffin blocks
of tumor tissue in GC.
Methods: 2000 GC patients from ten centers, patients were divided into a cohort using one
tumor tissue paraffin block (cohort 1, n=1000) and a cohort using dual tumor tissue paraffin
blocks (cohort 2, n=1000) when evaluating Her2/neu expression status by immunohistochemistry
(IHC). In cohort 2, the investigators combined the results from two different paraffin
blocks and used the higher one as the final score.
n/a
Observational Model: Cohort, Time Perspective: Prospective